These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28153487)

  • 1. Myeloma in the Real World: What Is Really Happening?
    Bergin K; McQuilten Z; Moore E; Wood E; Spencer A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):133-144.e1. PubMed ID: 28153487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The next generation of novel therapies for the management of relapsed multiple myeloma.
    Gonsalves WI; Milani P; Derudas D; Buadi FK
    Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.
    Richardson PG; San Miguel JF; Moreau P; Hajek R; Dimopoulos MA; Laubach JP; Palumbo A; Luptakova K; Romanus D; Skacel T; Kumar SK; Anderson KC
    Blood Cancer J; 2018 Nov; 8(11):109. PubMed ID: 30413684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
    Maciocia N; Melville A; Cheesman S; Sharpley F; Ramasamy K; Streetly M; Jenner M; Benjamin R; Schey S; Maciocia P; Popat R; D'sa S; Rismani A; Cerner A; Yong K; Rabin N
    Br J Haematol; 2017 Mar; 176(6):908-917. PubMed ID: 28211054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment landscape for relapsed and/or refractory multiple myeloma.
    Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
    Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
    Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
    Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.
    Ruggeri K; Maguire Á; Cook G
    JAMA Oncol; 2016 Nov; 2(11):1405-1406. PubMed ID: 27355621
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimising patient outcomes in myeloma.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S33-5. PubMed ID: 20472187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents and the paradigm of continuous treatment in multiple myeloma.
    Palumbo A
    Leuk Res; 2012 Nov; 36 Suppl 1():S1-2. PubMed ID: 23176718
    [No Abstract]   [Full Text] [Related]  

  • 17. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
    Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
    Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
    Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of complete response in outcomes in myeloma.
    Nooka A; Kaufman J; Lonial S
    Cancer J; 2009; 15(6):465-72. PubMed ID: 20010165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.